Cidara Therapeutics, Inc. (CDTX) Financials
Newest figures come from the 10-Q for Q3 FY2025, filed Nov 6, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CDTX SEC filings page.
Cidara Therapeutics, Inc. (CDTX) reported $1.3M in revenue for fiscal year 2024, down 94.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage business with shrinking commercial revenue still requires substantial research spending and operating cash.
Revenue contraction accelerated from$23.3M in FY2023 to$1.3M in FY2024, while R&D spending reached$71.9M and operating cash flow was-$176.5M . The combination indicates development activity expanded as reported sales receded, rather than sales growth funding that work.
Cash conversion is closely tracking accounting losses: FY2024 net loss was
Equity moved from negative
Financial Health Signals
Scored against emerging companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cidara Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cidara Therapeutics, Inc. held $189.8M in cash, cash equivalents and investments at the end of fiscal year 2024, and its operations used $176.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Cidara Therapeutics, Inc. scores 35/100 among other emerging companies.
Cidara Therapeutics, Inc. had 11M shares outstanding at the end of fiscal year 2024, against 91M in fiscal year 2023. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Cidara Therapeutics, Inc. scores 94/100 among other emerging companies.
Cidara Therapeutics, Inc. spent $71.9M on research and development in fiscal year 2024, which was 40.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Cidara Therapeutics, Inc. scores 71/100 among other emerging companies.
Cidara Therapeutics, Inc. reported revenue of $1.3M in fiscal year 2024, against $23.3M in fiscal year 2023. Revenue Progress ranks emerging companies on the three-year path of that line, and Cidara Therapeutics, Inc. scores 1/100 among other emerging companies.
Cidara Therapeutics, Inc.'s operations used $176.5M of cash in fiscal year 2024, against $22.4M used in fiscal year 2023. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Cidara Therapeutics, Inc. scores 5/100 among other emerging companies.
Cidara Therapeutics, Inc.'s cash, cash equivalents and investments came to $189.8M at the end of fiscal year 2024, against $51.5M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Cidara Therapeutics, Inc. scores 85/100 among other emerging companies.
Cidara Therapeutics, Inc. scores 13.39, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.6B) relative to total liabilities ($51.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cidara Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Cidara Therapeutics, Inc. reported a net loss of $169.8M while operations used $176.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Cidara Therapeutics, Inc. generated $0 in revenue in Q3 2025.
Cidara Therapeutics, Inc.'s EBITDA was -$88.6M in Q3 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 410.6% from the same quarter a year earlier. Against the prior quarter it is down 223.9%.
Cidara Therapeutics, Inc. reported -$83.2M in net income in Q3 2025. This represents a decrease of 420.7% from the same quarter a year earlier. Against the prior quarter it is down 223.6%.
Cash & Balance Sheet
Cidara Therapeutics, Inc. recorded an outflow of $40.6M in free cash flow in Q3 2025, representing a cash shortfall after capex. This represents a decrease of 10.4% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.
Cidara Therapeutics, Inc. held $293.7M in cash as of Q3 2025; long-term debt is not reported for that period.
Not reported for Q3 2025.
Margins & Returns
Cidara Therapeutics, Inc.'s ROE was -19.7% in Q3 2025, measuring profit generated per dollar of shareholder equity. This is down 5.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.6 percentage points.
Not reported for Q3 2025.
Not reported for Q3 2025.
Not reported for Q3 2025.
Capital Allocation
Cidara Therapeutics, Inc. invested $35.5M in research and development in Q3 2025. This represents an increase of 185.9% from the same quarter a year earlier. Against the prior quarter it is up 43.2%.
Cidara Therapeutics, Inc. reported no capital expenditure in Q3 2025. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q3 2025.
CDTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0-100.0% | $0-100.0% | N/A | $0-100.0% | $302K-94.1% | $2.8M-89.2% | N/A |
| R&D Expenses | $35.5M+185.9% | $24.8M+272.8% | $24.6M+315.6% | N/A | $12.4M+19.7% | $6.7M-23.1% | $5.9M-68.6% | N/A |
| SG&A Expenses | $8.1M+63.1% | $6.5M+37.0% | $6.2M+71.8% | N/A | $5.0M+50.5% | $4.7M+49.2% | $3.6M-19.3% | N/A |
| Operating Income | -$88.6M-409.5% | -$27.4M+71.5% | -$25.3M-195.8% | N/A | -$17.4M-289.3% | -$96.0M-1322.4% | -$8.5M-407.2% | N/A |
| EBITDA | -$88.6M-410.6% | -$27.4M+71.5% | -$25.2M-196.6% | N/A | -$17.4M-290.3% | -$95.9M-1327.1% | -$8.5M-402.4% | N/A |
| Income Tax | $0 | $0 | $0 | N/A | $0+100.0% | $0-100.0% | $0 | N/A |
| Net Income | -$83.2M-420.7% | -$25.7M+71.8% | -$23.5M-127.4% | N/A | -$16.0M-75.5% | -$91.2M-569.5% | -$10.3M-442.7% | N/A |
| EPS (Basic) | -$3.10-26.5% | -$1.65+91.7% | -$1.66+27.2% | -$4.22-13966.7% | -$2.45-21.3% | -$19.99-561.9% | -$2.28-480.0% | -$0.03+84.2% |
| EPS (Diluted) | -$3.10 | -$1.65 | -$1.66 | -$4.22 | -$2.45 | -$19.99-561.9% | -$2.28-480.0% | -$0.03+84.2% |
| Diluted Shares (Avg) | 27M | 16M | 14M | N/A | 7M | 5M+1.3% | 5M-10.3% | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
CDTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $518.6M+219.5% | $534.3M+208.2% | $191.7M+263.7% | $214.8M+220.4% | $162.3M+153.1% | $173.4M+153.7% | $52.7M-35.7% | $67.0M+41.2% |
| Current Assets | $442.8M+182.5% | $531.8M+215.4% | $188.8M+303.2% | $210.7M+246.3% | $156.8M+168.2% | $168.6M+169.0% | $46.8M-41.3% | $60.9M+35.0% |
| Cash & Equivalents | $293.7M+130.5% | $510.6M+210.6% | $168.2M+479.5% | $189.8M+430.6% | $127.4M+161.7% | $164.4M+225.9% | $29.0M-39.5% | $35.8M+9.3% |
| Short-Term Investments | $126.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $7.3M | $6.1M |
| Accounts Receivable | $1.9M+9.5% | $1.9M-20.9% | $1.7M-76.7% | $1.7M-88.0% | $1.7M-46.5% | $2.3M-57.2% | $7.3M-72.1% | $14.1M+141.3% |
| Long-Term Investments | $50.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $96.3M+106.1% | $33.2M-21.8% | $50.0M-29.0% | $51.5M-31.6% | $46.7M-33.3% | $42.4M-35.6% | $70.5M+5.4% | $75.2M+21.5% |
| Current Liabilities | $95.8M+116.2% | $32.3M-18.5% | $48.8M-25.4% | $49.6M-26.5% | $44.3M-11.7% | $39.6M-11.5% | $65.4M+37.8% | $67.4M+62.8% |
| Non-Current Liabilities | $424K-82.0% | $836K-69.9% | $1.2M-75.6% | $1.9M-75.3% | $2.4M-88.1% | $2.8M-86.9% | $5.1M-73.8% | $7.8M-61.9% |
| Total Equity | $422.4M+265.3% | $501.2M+282.8% | $141.7M+896.9% | $163.3M+2089.1% | $115.6M+2061.8% | $130.9M+5317.3% | -$17.8M-217.7% | -$8.2M+43.1% |
| Retained Earnings | -$743.7M-33.1% | -$660.5M-21.6% | -$634.7M-40.5% | -$611.3M-38.5% | -$559.0M-27.6% | -$543.0M-26.5% | -$451.8M-8.7% | -$441.4M-5.5% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
CDTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$40.6M-10.7% | -$41.0M+60.5% | -$21.9M-230.4% | -$29.4M-131.2% | -$36.7M-2145.7% | -$103.8M-3777.5% | -$6.6M+39.0% | -$12.7M+39.4% |
| Depreciation & Amortization | $28K-31.7% | $27K-27.0% | $36K0.0% | $40K+21.2% | $41K+86.4% | $37K+48.0% | $36K+12.5% | $33K+13.8% |
| Stock-Based Compensation | $3.2M+322.2% | $3.0M+320.3% | $1.7M+119.0% | N/A | $751K-5.7% | $703K-11.6% | $795K+24.2% | N/A |
| Capital Expenditures | $0-100.0% | $0 | $0-100.0% | $0-100.0% | $106K-15.9% | $0-100.0% | $23K-75.5% | $178K+1877.8% |
| Free Cash Flow | -$40.6M-10.4% | -$41.0M+60.5% | -$21.9M-229.2% | -$29.4M-128.0% | -$36.8M-1991.0% | -$103.8M-3922.5% | -$6.7M+39.3% | -$12.9M+38.6% |
| Investing Cash Flow | -$176.5M-166381.1% | $0 | $185K+904.3% | $0+100.0% | -$106K+15.9% | $0+100.0% | -$23K+75.5% | -$178K-1877.8% |
| Financing Cash Flow | $160K+187.9% | $383.4M+60.3% | $77K+182.8% | $98.2M+1227462.5% | -$182K | $239.1M+91721.1% | -$93K-100.4% | $8K-98.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CDTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -31782.8% | -302.3% | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -30201.7% | -365.4% | N/A |
| Return on Equity | -19.7%-5.9pp | -5.1%+64.5pp | -16.6% | N/A | -13.8% | -69.7%+494.0pp | N/A | N/A |
| Return on Assets | -16.1%-6.2pp | -4.8%+47.8pp | -12.3%+7.3pp | N/A | -9.8%+4.3pp | -52.6%-32.7pp | -19.6%-23.3pp | N/A |
| Current Ratio | 4.62+1.1x | 16.45+12.2x | 3.87+3.2x | 4.25+3.4x | 3.54+2.4x | 4.25+2.9x | 0.72-1.0x | 0.90-0.2x |
| Debt-to-Equity | 0.23-0.2x | 0.07-0.3x | 0.35 | 0.32 | 0.40 | 0.32-27.0x | N/A | N/A |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.00-0.1x | N/A | 0.00-0.1x | 0.00-0.1x | 0.05-0.3x | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -34364.2% | -235.9% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cidara Therapeutics, Inc. CDTX | FY2024 | $1.3M | -$169.8M | N/A | $1.6B | 49/100 |
| Aurinia Pharmaceuticals Inc AUPH | FY2025 | $283.1M | $287.2M | N/A | $2.2B | 56/100 |
| Ardelyx, Inc. ARDX | FY2025 | $407.3M | -$62.0M | -15.2% | $846.9M | 45/100 |
| Viridian Therapeutics, Inc. VRDN | FY2025 | $70.8M | -$342.6M | N/A | $2.1B | 67/100 |
| Vera Therapeutics, Inc. VERA | FY2025 | N/A | -$299.6M | N/A | $2.2B | — |
| Immunocore Holdings plc IMCR | FY2025 | $400.0M | -$35.5M | -8.9% | $1.5B | 65/100 |
Where Cidara Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Cidara Therapeutics, Inc.'s annual revenue?
Cidara Therapeutics, Inc. (CDTX) reported $1.3M in total revenue for fiscal year 2024. This represents a -94.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cidara Therapeutics, Inc.'s revenue growing?
Cidara Therapeutics, Inc. (CDTX) revenue declined by 94.5% year-over-year, from $23.3M to $1.3M in fiscal year 2024.
Is Cidara Therapeutics, Inc. profitable?
No, Cidara Therapeutics, Inc. (CDTX) reported a net income of -$169.8M in fiscal year 2024.
What is Cidara Therapeutics, Inc.'s EBITDA?
Cidara Therapeutics, Inc. (CDTX) had EBITDA of -$175.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cidara Therapeutics, Inc.'s return on equity (ROE)?
Cidara Therapeutics, Inc. (CDTX) has a return on equity of -104.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Cidara Therapeutics, Inc.'s free cash flow?
Cidara Therapeutics, Inc. (CDTX) recorded an outflow of $176.7M in free cash flow during fiscal year 2024. This represents a -670.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cidara Therapeutics, Inc.'s operating cash flow?
Cidara Therapeutics, Inc. (CDTX) recorded an outflow of $176.5M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Cidara Therapeutics, Inc.'s total assets?
Cidara Therapeutics, Inc. (CDTX) had $214.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Cidara Therapeutics, Inc.'s capital expenditures?
Cidara Therapeutics, Inc. (CDTX) invested $129K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Cidara Therapeutics, Inc. spend on research and development?
Cidara Therapeutics, Inc. (CDTX) invested $71.9M in research and development during fiscal year 2024.
What is Cidara Therapeutics, Inc.'s current ratio?
Cidara Therapeutics, Inc. (CDTX) had a current ratio of 4.25 as of fiscal year 2024, which is generally considered healthy.
What is Cidara Therapeutics, Inc.'s debt-to-equity ratio?
Cidara Therapeutics, Inc. (CDTX) had a debt-to-equity ratio of 0.32 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cidara Therapeutics, Inc.'s return on assets (ROA)?
Cidara Therapeutics, Inc. (CDTX) had a return on assets of -79.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
How does Cidara Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, Cidara Therapeutics, Inc. (CDTX) held $189.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $176.5M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Cidara Therapeutics, Inc.'s Altman Z-Score?
Cidara Therapeutics, Inc. (CDTX) has an Altman Z-Score of 13.39, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cidara Therapeutics, Inc.'s Piotroski F-Score?
Cidara Therapeutics, Inc. (CDTX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cidara Therapeutics, Inc.'s earnings high quality?
Cidara Therapeutics, Inc. (CDTX) reported a net loss of $169.8M while operations used $176.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cidara Therapeutics, Inc.?
Cidara Therapeutics, Inc. (CDTX) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.